US3547119A
(en)
|
1967-12-08 |
1970-12-15 |
Baxter Laboratories Inc |
Catheter assembly
|
US4211771A
(en)
|
1971-06-01 |
1980-07-08 |
Robins Ronald K |
Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
|
US3798209A
(en)
|
1971-06-01 |
1974-03-19 |
Icn Pharmaceuticals |
1,2,4-triazole nucleosides
|
US4311137A
(en)
|
1980-04-30 |
1982-01-19 |
Sherwood Medical Industries Inc. |
Infusion device
|
US4531937A
(en)
|
1983-01-24 |
1985-07-30 |
Pacesetter Systems, Inc. |
Introducer catheter apparatus and method of use
|
CS263951B1
(en)
|
1985-04-25 |
1989-05-12 |
Antonin Holy |
9-(phosponylmethoxyalkyl)adenines and method of their preparation
|
ATE108794T1
(de)
|
1985-05-15 |
1994-08-15 |
Wellcome Found |
Therapeutische nucleoside und deren herstellung.
|
US4806347A
(en)
|
1985-12-11 |
1989-02-21 |
Schering Corporation |
Interferon combinations
|
US4755173A
(en)
|
1986-02-25 |
1988-07-05 |
Pacesetter Infusion, Ltd. |
Soft cannula subcutaneous injection set
|
CS264222B1
(en)
|
1986-07-18 |
1989-06-13 |
Holy Antonin |
N-phosphonylmethoxyalkylderivatives of bases of pytimidine and purine and method of use them
|
US5082659A
(en)
|
1986-10-06 |
1992-01-21 |
Board Of Regents, The University Of Texas System |
Methods and compositions employing interferon-gamma
|
US5190751A
(en)
|
1987-01-20 |
1993-03-02 |
Schering Corporation |
Treatment of certain leukemias with a combination of gamma interferon and alpha interferon
|
ES2039276T3
(es)
|
1987-01-20 |
1993-09-16 |
Schering Corporation |
Uso de una combinacion de interferon gamma e interferon alfa para la preparacion de un medicamento para el tratamiento de ciertas leucemias.
|
WO1988009673A1
(fr)
|
1987-06-02 |
1988-12-15 |
Schering Corporation |
Traitement de l'hepatite b de type chronique avec une combinaison d'interferons alpha et gamma humains recombinants
|
GB8815265D0
(en)
|
1988-06-27 |
1988-08-03 |
Wellcome Found |
Therapeutic nucleosides
|
US5552558A
(en)
|
1989-05-23 |
1996-09-03 |
Abbott Laboratories |
Retroviral protease inhibiting compounds
|
US5232928A
(en)
|
1989-07-25 |
1993-08-03 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Tetrahydroisoquinoline amides
|
US5518729A
(en)
|
1989-11-22 |
1996-05-21 |
Margolin; Solomon B. |
Compositions and methods for reparation and prevention of fibrotic lesions
|
US5716632A
(en)
|
1989-11-22 |
1998-02-10 |
Margolin; Solomon B. |
Compositions and methods for reparation and prevention of fibrotic lesions
|
US5310562A
(en)
|
1989-11-22 |
1994-05-10 |
Margolin Solomon B |
Composition and method for reparation and prevention of fibrotic lesions
|
US5372808A
(en)
|
1990-10-17 |
1994-12-13 |
Amgen Inc. |
Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
|
US5610054A
(en)
|
1992-05-14 |
1997-03-11 |
Ribozyme Pharmaceuticals, Inc. |
Enzymatic RNA molecule targeted against Hepatitis C virus
|
US5382657A
(en)
|
1992-08-26 |
1995-01-17 |
Hoffmann-La Roche Inc. |
Peg-interferon conjugates
|
US5545143A
(en)
|
1993-01-21 |
1996-08-13 |
T. S. I. Medical |
Device for subcutaneous medication delivery
|
ES2174915T3
(es)
|
1993-11-10 |
2002-11-16 |
Enzon Inc |
Productos de conjugacion mejorados de un interferon con un polimero.
|
US5624949A
(en)
|
1993-12-07 |
1997-04-29 |
Eli Lilly And Company |
Protein kinase C inhibitors
|
US6693072B2
(en)
|
1994-06-02 |
2004-02-17 |
Aventis Pharmaceuticals Inc. |
Elastase inhibitors
|
US5500208A
(en)
|
1994-06-07 |
1996-03-19 |
The Procter & Gamble Company |
Oral compositions comprising a novel tripeptide
|
US5756466A
(en)
|
1994-06-17 |
1998-05-26 |
Vertex Pharmaceuticals, Inc. |
Inhibitors of interleukin-1β converting enzyme
|
US5847135A
(en)
|
1994-06-17 |
1998-12-08 |
Vertex Pharmaceuticals, Incorporated |
Inhibitors of interleukin-1β converting enzyme
|
US5824784A
(en)
|
1994-10-12 |
1998-10-20 |
Amgen Inc. |
N-terminally chemically modified protein compositions and methods
|
IL116730A0
(en)
|
1995-01-13 |
1996-05-14 |
Amgen Inc |
Chemically modified interferon
|
US6090822A
(en)
|
1995-03-03 |
2000-07-18 |
Margolin; Solomon B. |
Treatment of cytokine growth factor caused disorders
|
GB9517022D0
(en)
|
1995-08-19 |
1995-10-25 |
Glaxo Group Ltd |
Medicaments
|
US5908621A
(en)
|
1995-11-02 |
1999-06-01 |
Schering Corporation |
Polyethylene glycol modified interferon therapy
|
US5980884A
(en)
|
1996-02-05 |
1999-11-09 |
Amgen, Inc. |
Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon
|
US5908121A
(en)
|
1996-03-11 |
1999-06-01 |
Dardashti; Shahriar |
Adjustable display assembly
|
US5633388A
(en)
|
1996-03-29 |
1997-05-27 |
Viropharma Incorporated |
Compounds, compositions and methods for treatment of hepatitis C
|
AU2933797A
(en)
|
1996-05-10 |
1997-12-05 |
Schering Corporation |
Synthetic inhibitors of hepatitis c virus ns3 protease
|
PL194025B1
(pl)
|
1996-10-18 |
2007-04-30 |
Vertex Pharma |
Inhibitory proteaz serynowych, a zwłaszcza proteazy wirusa NS3 zapalenia wątroby C, kompozycja farmaceutyczna i zastosowanie inhibitorów proteaz serynowych
|
GB9623908D0
(en)
|
1996-11-18 |
1997-01-08 |
Hoffmann La Roche |
Amino acid derivatives
|
US5968895A
(en)
|
1996-12-11 |
1999-10-19 |
Praecis Pharmaceuticals, Inc. |
Pharmaceutical formulations for sustained drug delivery
|
AU7127298A
(en)
|
1997-04-14 |
1998-11-11 |
Emory University |
Serine protease inhibitors
|
GB9707659D0
(en)
|
1997-04-16 |
1997-06-04 |
Peptide Therapeutics Ltd |
Hepatitis C NS3 Protease inhibitors
|
ATE291032T1
(de)
|
1997-08-11 |
2005-04-15 |
Boehringer Ingelheim Ca Ltd |
Hepatitis c inhibitor peptide
|
ES2234144T3
(es)
|
1997-08-11 |
2005-06-16 |
Boehringer Ingelheim (Canada) Ltd. |
Analogos de peptidos inhibidores de la hepatitis c.
|
US6767991B1
(en)
|
1997-08-11 |
2004-07-27 |
Boehringer Ingelheim (Canada) Ltd. |
Hepatitis C inhibitor peptides
|
US6172046B1
(en)
|
1997-09-21 |
2001-01-09 |
Schering Corporation |
Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
|
US5985263A
(en)
|
1997-12-19 |
1999-11-16 |
Enzon, Inc. |
Substantially pure histidine-linked protein polymer conjugates
|
IT1299134B1
(it)
|
1998-02-02 |
2000-02-29 |
Angeletti P Ist Richerche Bio |
Procedimento per la produzione di peptidi con proprieta' inibitrici della proteasi ns3 del virus hcv, peptidi cosi' ottenibili e peptidi
|
JP4690545B2
(ja)
|
1998-03-31 |
2011-06-01 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
セリンプロテアーゼ、特にc型肝炎ウイルスns3プロテアーゼの阻害因子
|
GB9812523D0
(en)
|
1998-06-10 |
1998-08-05 |
Angeletti P Ist Richerche Bio |
Peptide inhibitors of hepatitis c virus ns3 protease
|
US6323180B1
(en)
|
1998-08-10 |
2001-11-27 |
Boehringer Ingelheim (Canada) Ltd |
Hepatitis C inhibitor tri-peptides
|
AR022061A1
(es)
|
1998-08-10 |
2002-09-04 |
Boehringer Ingelheim Ca Ltd |
Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos.
|
US6277830B1
(en)
|
1998-10-16 |
2001-08-21 |
Schering Corporation |
5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon
|
US7157430B2
(en)
|
1998-10-22 |
2007-01-02 |
Idun Pharmaceuticals, Inc. |
(Substituted)acyl dipeptidyl inhibitors of the ICE/CED-3 family of cysteine proteases
|
US6245740B1
(en)
|
1998-12-23 |
2001-06-12 |
Amgen Inc. |
Polyol:oil suspensions for the sustained release of proteins
|
UA74546C2
(en)
|
1999-04-06 |
2006-01-16 |
Boehringer Ingelheim Ca Ltd |
Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
|
US6608027B1
(en)
|
1999-04-06 |
2003-08-19 |
Boehringer Ingelheim (Canada) Ltd |
Macrocyclic peptides active against the hepatitis C virus
|
WO2000066623A2
(fr)
|
1999-05-04 |
2000-11-09 |
Boehringer Ingelheim (Canada) Ltd. |
Systeme a base de cellules de remplacement et procede de dosage de l'activite de la protease ns3 du virus de l'hepatite c
|
US7256005B2
(en)
|
1999-08-10 |
2007-08-14 |
The Chancellor, Masters And Scholars Of The University Of Oxford |
Methods for identifying iminosugar derivatives that inhibit HCV p7 ion channel activity
|
ES2240446T3
(es)
|
2000-04-03 |
2005-10-16 |
Vertex Pharma |
Inhibidores de serina proteasas, particularmente la proteasa ns3 del virus de la hepatitis c.
|
DE60137207D1
(de)
|
2000-04-05 |
2009-02-12 |
Schering Corp |
Makrozyklische inhibitoren der ns3-serinprotease des hepatitis c-virus mit stickstoffhaltigen zyklischen p2-gruppen
|
SK14952002A3
(sk)
|
2000-04-19 |
2003-03-04 |
Schering Corporation |
Makrocyklické zlúčeniny, farmaceutický prostriedok s ich obsahom a ich použitie
|
PL206255B1
(pl)
|
2000-07-21 |
2010-07-30 |
Dendreon Corporationdendreon Corporation |
Inhibitor proteazy wirusa zapalenia wątroby C, zawierająca go kompozycja farmaceutyczna i zastosowanie inhibitora do wytwarzania leku do leczenia chorób związanych z HCV oraz zastosowanie do wytwarzania kompozycji do stosowania w kombinowanej terapii
|
US7244721B2
(en)
|
2000-07-21 |
2007-07-17 |
Schering Corporation |
Peptides as NS3-serine protease inhibitors of hepatitis C virus
|
JP3889708B2
(ja)
|
2000-11-20 |
2007-03-07 |
ブリストル−マイヤーズ スクイブ カンパニー |
C型肝炎トリペプチド阻害剤
|
EP1408986B1
(fr)
|
2001-05-08 |
2008-09-24 |
Yale University |
Composes proteomimetiques et procedes correspondants
|
CN100402549C
(zh)
|
2001-07-11 |
2008-07-16 |
沃泰克斯药物股份有限公司 |
桥连二环的丝氨酸蛋白酶抑制剂
|
US6867185B2
(en)
|
2001-12-20 |
2005-03-15 |
Bristol-Myers Squibb Company |
Inhibitors of hepatitis C virus
|
CA2369711A1
(fr)
|
2002-01-30 |
2003-07-30 |
Boehringer Ingelheim (Canada) Ltd. |
Peptides macrocycliques qui agissent contre le virus de l'hepatite c
|
US7119072B2
(en)
|
2002-01-30 |
2006-10-10 |
Boehringer Ingelheim (Canada) Ltd. |
Macrocyclic peptides active against the hepatitis C virus
|
CA2369970A1
(fr)
|
2002-02-01 |
2003-08-01 |
Boehringer Ingelheim (Canada) Ltd. |
Tri-peptides inhibiteur de l'hepatite c
|
CA2370396A1
(fr)
|
2002-02-01 |
2003-08-01 |
Boehringer Ingelheim (Canada) Ltd. |
Tri-peptides inhibiteur de l'hepatite c
|
US6642204B2
(en)
|
2002-02-01 |
2003-11-04 |
Boehringer Ingelheim International Gmbh |
Hepatitis C inhibitor tri-peptides
|
US7091184B2
(en)
|
2002-02-01 |
2006-08-15 |
Boehringer Ingelheim International Gmbh |
Hepatitis C inhibitor tri-peptides
|
CA2370400A1
(fr)
|
2002-02-01 |
2003-08-01 |
Boehringer Ingelheim (Canada) Ltd. |
Tri-peptides inhibiteur de l'hepatite c
|
US6828301B2
(en)
|
2002-02-07 |
2004-12-07 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical compositions for hepatitis C viral protease inhibitors
|
NZ561851A
(en)
|
2002-04-11 |
2009-05-31 |
Vertex Pharma |
Inhibitors of serine proteases, particularly hepatitis C virus NS3 - NS4 protease
|
WO2003091264A2
(fr)
|
2002-04-26 |
2003-11-06 |
Gilead Sciences, Inc. |
Inhibiteurs non nucleosidiques de la transcriptase inverse
|
AU2003299519A1
(en)
|
2002-05-20 |
2004-05-04 |
Bristol-Myers Squibb Company |
Hepatitis c virus inhibitors
|
US20060199773A1
(en)
|
2002-05-20 |
2006-09-07 |
Sausker Justin B |
Crystalline forms of (1R,2S)-N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(6-methoxy-1-isoquinolinyl)oxy]-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-ethenyl-cyclopropanecarboxamide, monopotassium salt
|
MY140680A
(en)
|
2002-05-20 |
2010-01-15 |
Bristol Myers Squibb Co |
Hepatitis c virus inhibitors
|
WO2004043339A2
(fr)
|
2002-05-20 |
2004-05-27 |
Bristol-Myers Squibb Company |
Inhibiteurs du virus de l'hepatite c a base de cycloalkyle p1' substitue
|
EP1506000B9
(fr)
|
2002-05-20 |
2011-08-31 |
Bristol-Myers Squibb Company |
Sulfamides heterocycliques en tant qu'inhibiteurs du virus de l'hepatite c
|
US20040033959A1
(en)
|
2002-07-19 |
2004-02-19 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Pharmaceutical compositions for hepatitis C viral protease inhibitors
|
US20040138109A1
(en)
|
2002-09-30 |
2004-07-15 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Potent inhibitor of HCV serine protease
|
PL199412B1
(pl)
|
2002-10-15 |
2008-09-30 |
Boehringer Ingelheim Int |
Nowe kompleksy rutenu jako (pre)katalizatory reakcji metatezy, pochodne 2-alkoksy-5-nitrostyrenu jako związki pośrednie i sposób ich wytwarzania
|
US20050075279A1
(en)
|
2002-10-25 |
2005-04-07 |
Boehringer Ingelheim International Gmbh |
Macrocyclic peptides active against the hepatitis C virus
|
US7601709B2
(en)
|
2003-02-07 |
2009-10-13 |
Enanta Pharmaceuticals, Inc. |
Macrocyclic hepatitis C serine protease inhibitors
|
US20040180815A1
(en)
|
2003-03-07 |
2004-09-16 |
Suanne Nakajima |
Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors
|
KR100940619B1
(ko)
|
2003-02-07 |
2010-02-05 |
이난타 파마슈티칼스, 인코포레이티드 |
마크로사이클릭 씨형 간염 세린 단백효소 억제제
|
JP4550824B2
(ja)
|
2003-03-05 |
2010-09-22 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
C型肝炎抑制化合物
|
UY28240A1
(es)
|
2003-03-27 |
2004-11-08 |
Boehringer Ingelheim Pharma |
Fases cristalinas de un potente inhibidor de la hcv
|
CA2520886A1
(fr)
|
2003-04-02 |
2004-11-04 |
Boehringer Ingelheim International Gmbh |
Compositions pharmaceutiques contenant des inhibiteurs de protease virale de l'hepatite c
|
JP2007523833A
(ja)
|
2003-04-10 |
2007-08-23 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
ルテニウム錯体触媒メタセシス反応による大環状化合物の製造方法
|
JP4231524B2
(ja)
|
2003-04-10 |
2009-03-04 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
大環状化合物の製造方法
|
TW200510391A
(en)
*
|
2003-04-11 |
2005-03-16 |
Vertex Pharma |
Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
|
ES2386161T3
(es)
|
2003-04-16 |
2012-08-10 |
Bristol-Myers Squibb Company |
Proceso para separar una mezcla de enantiómeros de éster alquílico usando una enzima
|
US7176208B2
(en)
|
2003-04-18 |
2007-02-13 |
Enanta Pharmaceuticals, Inc. |
Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
|
ATE490788T1
(de)
|
2003-04-25 |
2010-12-15 |
Gilead Sciences Inc |
Antivirale phosphonate analoge
|
WO2004096285A2
(fr)
|
2003-04-25 |
2004-11-11 |
Gilead Sciences, Inc. |
Analogues anti-infectieux du phosphonate
|
US20040229848A1
(en)
|
2003-05-05 |
2004-11-18 |
Hans-Ulrich Demuth |
Glutaminyl based DP IV-inhibitors
|
US7273851B2
(en)
|
2003-06-05 |
2007-09-25 |
Enanta Pharmaceuticals, Inc. |
Tri-peptide hepatitis C serine protease inhibitors
|
US7125845B2
(en)
|
2003-07-03 |
2006-10-24 |
Enanta Pharmaceuticals, Inc. |
Aza-peptide macrocyclic hepatitis C serine protease inhibitors
|
PE20050374A1
(es)
|
2003-09-05 |
2005-05-30 |
Vertex Pharma |
Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc
|
AU2004274468B2
(en)
|
2003-09-18 |
2009-07-23 |
Vertex Pharmaceuticals, Incorporated |
Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
|
MXPA06003141A
(es)
|
2003-09-22 |
2006-06-05 |
Boehringer Ingelheim Int |
Peptidos macrociclicos activos contra el virus de la hepatitis c.
|
JP4525982B2
(ja)
|
2003-09-26 |
2010-08-18 |
シェーリング コーポレイション |
C型肝炎ウイルスのns3セリンプロテアーゼの大環状インヒビター
|
KR20120010278A
(ko)
|
2003-10-10 |
2012-02-02 |
버텍스 파마슈티칼스 인코포레이티드 |
세린 프로테아제, 특히 hcv ns3-ns4a 프로테아제의 억제제
|
PL1680137T3
(pl)
*
|
2003-10-14 |
2013-04-30 |
F Hoffmann La Roche Ltd |
Makrocykliczny kwas karboksylowy i związek acylosulfonamidowy jako inhibitor replikacji HCV
|
US7491794B2
(en)
|
2003-10-14 |
2009-02-17 |
Intermune, Inc. |
Macrocyclic compounds as inhibitors of viral replication
|
CA2551074A1
(fr)
|
2003-10-27 |
2005-05-12 |
Vertex Pharmaceuticals Incorporated |
Mutants resistant a la protease hcv ns3-ns4a
|
US7132504B2
(en)
|
2003-11-12 |
2006-11-07 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
WO2005053735A1
(fr)
|
2003-11-20 |
2005-06-16 |
Boehringer Ingelheim International Gmbh |
Procede d'elimination de metaux de transition, notamment, a partir de produits de reaction de metathese
|
US7309708B2
(en)
|
2003-11-20 |
2007-12-18 |
Birstol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7135462B2
(en)
|
2003-11-20 |
2006-11-14 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
DE602004019973D1
(de)
|
2003-12-08 |
2009-04-23 |
Boehringer Ingelheim Int |
Abtrennung von ruthenium-nebenprodukten durch behandlung mit überkritischen flüssigkeiten
|
AU2004298498B2
(en)
|
2003-12-11 |
2008-09-11 |
Schering Corporation |
Inhibitors of hepatitis C virus NS3/NS4a serine protease
|
ES2358333T3
(es)
*
|
2004-01-21 |
2011-05-09 |
Boehringer Ingelheim International Gmbh |
Péptidos macrocíclicos con acción contra el virus de la hepatitis c.
|
EP1711514B1
(fr)
|
2004-01-28 |
2008-12-03 |
Boehringer Ingelheim International GmbH |
Methode pour suppresser des metaux de transition dans des solutions de reaction contentant des complexes de metaux de transition
|
ES2336009T3
(es)
|
2004-01-30 |
2010-04-07 |
Medivir Ab |
Inhibidores de la ns-3 serina proteasa del vhc.
|
WO2005077969A2
(fr)
|
2004-02-04 |
2005-08-25 |
Vertex Pharmaceuticals Incorporated |
Inhibiteurs de proteases serines, en particulier de la protease hcv ns3-ns4a
|
EP1939213B1
(fr)
|
2004-02-27 |
2010-08-25 |
Schering Corporation |
Nouveaux composés en tant qu'inhibiteurs de la sérine protéase NS3 du virus de l'hépatite C
|
WO2005087730A1
(fr)
|
2004-02-27 |
2005-09-22 |
Schering Corporation |
Composes de proline fusionnes a 3,4-(cyclopentyl) en tant qu'inhibiteurs de la protease serine ns3 du virus de l'hepatite c
|
US7816326B2
(en)
|
2004-02-27 |
2010-10-19 |
Schering Corporation |
Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease
|
KR20060124725A
(ko)
|
2004-02-27 |
2006-12-05 |
쉐링 코포레이션 |
C형 간염 바이러스 ns3 프로테아제의 억제제
|
JP4874227B2
(ja)
|
2004-02-27 |
2012-02-15 |
シェーリング コーポレイション |
C型肝炎ウイルスのns3セリンプロテアーゼインヒビターとしての環状p4’sを有する新規ケトアミド
|
AU2005224092A1
(en)
|
2004-03-15 |
2005-09-29 |
Boehringer Ingelheim International, Gmbh |
Process for preparing macrocyclic dipeptides which are suitable for the treatment of hepatitis C viral infections
|
WO2005097820A1
(fr)
|
2004-04-06 |
2005-10-20 |
Korea Research Institute Of Bioscience And Biotechnology |
Peptides destines a inhiber la fonction mdm2
|
CN1984922A
(zh)
|
2004-05-20 |
2007-06-20 |
先灵公司 |
用作丙型肝炎病毒ns3丝氨酸蛋白酶抑制剂的取代脯氨酸
|
US7514557B2
(en)
|
2004-05-25 |
2009-04-07 |
Boehringer Ingelheim International Gmbh |
Process for preparing acyclic HCV protease inhibitors
|
US7939538B2
(en)
|
2004-06-28 |
2011-05-10 |
Amgen Inc. |
Compounds, compositions and methods for prevention and treatment of inflammatory and immunoregulatory disorders and diseases
|
DE102004033312A1
(de)
|
2004-07-08 |
2006-01-26 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Kontinuierliches Metatheseverfahren mit Ruthenium-Katalysatoren
|
AP2461A
(en)
|
2004-07-16 |
2012-09-14 |
Gilead Sciences Inc |
Antiviral compounds
|
UY29016A1
(es)
|
2004-07-20 |
2006-02-24 |
Boehringer Ingelheim Int |
Analogos de dipeptidos inhibidores de la hepatitis c
|
JP4914355B2
(ja)
|
2004-07-20 |
2012-04-11 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
C型肝炎インヒビターペプチド類似体
|
CN101068828A
(zh)
|
2004-08-27 |
2007-11-07 |
先灵公司 |
用作丙型肝炎病毒ns3丝氨酸蛋白酶抑制剂的酰基磺酰胺化合物
|
EP1794179A1
(fr)
|
2004-09-17 |
2007-06-13 |
Boehringer Ingelheim International Gmbh |
Réaction de métathèse cyclisante en milieu fluide supercritique
|
CA2577831A1
(fr)
|
2004-09-17 |
2006-03-30 |
Boehringer Ingelheim International Gmbh |
Procede de fabrication d'inhibiteurs de protease hcv macrocycliques
|
EP2332527A3
(fr)
|
2004-10-20 |
2011-11-16 |
Resverlogix Corp. |
Flavanoides et Isoflavanoides pour la prevention et le traitement de maladies cardio-vasculaires
|
DE102005002336A1
(de)
|
2005-01-17 |
2006-07-20 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Durchführung von kontinuierlichen Olefin-Ringschluss-Metathesen in komprimiertem Kohlendioxid
|
US7323447B2
(en)
|
2005-02-08 |
2008-01-29 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7524831B2
(en)
|
2005-03-02 |
2009-04-28 |
Schering Corporation |
Treatments for Flaviviridae virus infection
|
AU2006220887B2
(en)
|
2005-03-04 |
2010-11-04 |
The Rockefeller University |
Infectious, chimeric Hepatitis C Virus, methods of producing the same and methods of use thereof
|
KR101514953B1
(ko)
|
2005-03-08 |
2015-04-24 |
베링거 인겔하임 인터내셔날 게엠베하 |
매크로사이클릭 화합물의 제조방법
|
WO2006113942A2
(fr)
|
2005-04-20 |
2006-10-26 |
Schering Corporation |
Procede d'inhibition de l'activite de cathepsine
|
CA2606195C
(fr)
|
2005-05-02 |
2015-03-31 |
Merck And Co., Inc. |
Inhibiteurs de la protease ns3 du vhc
|
EP1899368A2
(fr)
|
2005-05-26 |
2008-03-19 |
Schering Corporation |
Fusion interferon-igg
|
WO2006130688A2
(fr)
|
2005-06-02 |
2006-12-07 |
Schering Corporation |
Procedes de dosage asymetrique
|
US20060275366A1
(en)
|
2005-06-02 |
2006-12-07 |
Schering Corporation |
Controlled-release formulation
|
AU2006252553B2
(en)
|
2005-06-02 |
2012-03-29 |
Merck Sharp & Dohme Corp. |
Combination of HCV protease inhibitors with a surfactant
|
US20060276405A1
(en)
|
2005-06-02 |
2006-12-07 |
Schering Corporation |
Methods for treating hepatitis C
|
US20060281689A1
(en)
|
2005-06-02 |
2006-12-14 |
Schering Corporation |
Method for modulating activity of HCV protease through use of a novel HCV protease inhibitor to reduce duration of treatment period
|
US20070021351A1
(en)
|
2005-06-02 |
2007-01-25 |
Schering Corporation |
Liver/plasma concentration ratio for dosing hepatitis C virus protease inhibitor
|
WO2006130553A2
(fr)
|
2005-06-02 |
2006-12-07 |
Schering Corporation |
Methode destinee au traitement de troubles et de maladies ne repondant pas aux interferons, dans laquelle est utilise un inhibiteur de la protease du vhc
|
US20060276407A1
(en)
|
2005-06-02 |
2006-12-07 |
Schering Corporation |
Methods of treating hepatitis C virus
|
US20060276404A1
(en)
|
2005-06-02 |
2006-12-07 |
Anima Ghosal |
Medicaments and methods combining a HCV protease inhibitor and an AKR competitor
|
PL1891089T3
(pl)
|
2005-06-02 |
2015-05-29 |
Merck Sharp & Dohme |
Inhibitory proteazy HCV w połączeniu z pokarmem
|
US7608592B2
(en)
|
2005-06-30 |
2009-10-27 |
Virobay, Inc. |
HCV inhibitors
|
US7601686B2
(en)
|
2005-07-11 |
2009-10-13 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
TWI389908B
(zh)
|
2005-07-14 |
2013-03-21 |
Gilead Sciences Inc |
抗病毒化合物類
|
TWI387603B
(zh)
|
2005-07-20 |
2013-03-01 |
Merck Sharp & Dohme |
Hcv ns3蛋白酶抑制劑
|
EP2305696A3
(fr)
|
2005-07-25 |
2011-10-12 |
Intermune, Inc. |
Inhibiteurs macrocycliques de la multiplication du virus de L'Hépatite C
|
US7700552B2
(en)
|
2005-07-29 |
2010-04-20 |
Medivir Ab |
Macrocyclic inhibitors of hepatitis C virus
|
DK1919898T3
(da)
|
2005-07-29 |
2011-05-02 |
Tibotec Pharm Ltd |
Makrocykliske inhibitorer af hepatitis-C-virus
|
PE20070343A1
(es)
|
2005-07-29 |
2007-05-12 |
Medivir Ab |
Inhibidores macrociclicos del virus de la hepatitis c
|
WO2007016476A2
(fr)
|
2005-08-01 |
2007-02-08 |
Phenomix Corporation |
Inhibiteurs de la sérine protéase de l'hépatite c et emploi desdits inhibiteurs
|
KR20080056295A
(ko)
|
2005-10-11 |
2008-06-20 |
인터뮨, 인크. |
C형 간염 바이러스 복제를 억제하기 위한 화합물 및 방법
|
US7772183B2
(en)
|
2005-10-12 |
2010-08-10 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7741281B2
(en)
|
2005-11-03 |
2010-06-22 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7705138B2
(en)
*
|
2005-11-11 |
2010-04-27 |
Vertex Pharmaceuticals Incorporated |
Hepatitis C virus variants
|
WO2007057317A1
(fr)
|
2005-11-16 |
2007-05-24 |
F. Hoffmann-La Roche Ag |
DERIVES INNOVANTS DE LA PYRROLIDINE EN TANT QU'INHIBITEURS DU FACTEUR DE COAGULATION Xa
|
CA2641859A1
(fr)
|
2006-02-09 |
2007-08-16 |
Schering Corporation |
Combinaisons comprenant un ou plusieurs inhibiteurs de protease du vhc et un ou plusieurs inhibiteurs de polymerase du vhc, et methodes de traitement associees
|
MX2008011868A
(es)
|
2006-03-16 |
2008-12-15 |
Vertex Pharma |
Inhibidores deuterados de la proteasa de la hepatitis c.
|
US20070287664A1
(en)
|
2006-03-23 |
2007-12-13 |
Schering Corporation |
Combinations of HCV protease inhibitor(s) and CYP3A4 inhibitor(s), and methods of treatment related thereto
|
NZ571826A
(en)
|
2006-04-11 |
2012-01-12 |
Novartis Ag |
HCV/HIV inhibitors and their uses
|
US7728148B2
(en)
|
2006-06-06 |
2010-06-01 |
Enanta Pharmaceuticals, Inc. |
Acyclic oximyl hepatitis C protease inhibitors
|
US9526769B2
(en)
|
2006-06-06 |
2016-12-27 |
Enanta Pharmaceuticals, Inc. |
Macrocylic oximyl hepatitis C protease inhibitors
|
US20080187516A1
(en)
|
2006-06-06 |
2008-08-07 |
Ying Sun |
Acyclic oximyl hepatitis c protease inhibitors
|
US20090203008A1
(en)
|
2006-06-08 |
2009-08-13 |
Ludmerer Steven W |
Rapid method to determine inhibitor sensitivity of NS3/4A protease sequences cloned from clinical samples
|
UY30437A1
(es)
|
2006-06-26 |
2008-01-31 |
Enanta Pharm Inc |
Quinoxalinil macroceclicos inhibidores de serina proteasa del virus de la hepatitis c
|
RU2008152171A
(ru)
|
2006-07-05 |
2010-08-10 |
Интермьюн, Инк. (Us) |
Новые ингибиторы вирусной репликации гепатита с
|
EP2049474B1
(fr)
|
2006-07-11 |
2015-11-04 |
Bristol-Myers Squibb Company |
Inhibiteurs du virus de l'hépatite c
|
ES2448494T3
(es)
|
2006-07-13 |
2014-03-14 |
Achillion Pharmaceuticals, Inc. |
Péptidos de 4-amino-4-oxobutanoilo en calidad de inhibidores de la replicación viral
|
US20090035267A1
(en)
|
2007-07-31 |
2009-02-05 |
Moore Joel D |
Acyclic, pyridazinone-derived hepatitis c serine protease inhibitors
|
WO2008019303A2
(fr)
|
2006-08-04 |
2008-02-14 |
Enanta Pharmaceuticals, Inc. |
Inhibiteurs de sérine protéases de l'hépatite c macrocycliques de type pyridazinonyle
|
US7635683B2
(en)
|
2006-08-04 |
2009-12-22 |
Enanta Pharmaceuticals, Inc. |
Quinoxalinyl tripeptide hepatitis C virus inhibitors
|
CN101674844A
(zh)
|
2006-08-04 |
2010-03-17 |
英安塔制药有限公司 |
四唑基大环类c型肝炎丝氨酸蛋白酶抑制剂
|
US7605126B2
(en)
|
2006-08-11 |
2009-10-20 |
Enanta Pharmaceuticals, Inc. |
Acylaminoheteroaryl hepatitis C virus protease inhibitors
|
WO2008022006A2
(fr)
|
2006-08-11 |
2008-02-21 |
Enanta Pharmaceuticals, Inc. |
Inhibiteurs de protéase du virus de l'hépatite c arylalcoxyle
|
US7687459B2
(en)
*
|
2006-08-11 |
2010-03-30 |
Enanta Pharmaceuticals, Inc. |
Arylalkoxyl hepatitis C virus protease inhibitors
|
US20090098085A1
(en)
|
2006-08-11 |
2009-04-16 |
Ying Sun |
Tetrazolyl acyclic hepatitis c serine protease inhibitors
|
US20080038225A1
(en)
|
2006-08-11 |
2008-02-14 |
Ying Sun |
Triazolyl acyclic hepatitis c serine protease inhibitors
|
WO2008021960A2
(fr)
|
2006-08-11 |
2008-02-21 |
Enanta Pharmaceuticals, Inc. |
Inhibiteurs triazolyle macrocycliques de la sérine protéase de l'hépatite c
|
US20090155209A1
(en)
|
2007-05-03 |
2009-06-18 |
Blatt Lawrence M |
Novel macrocyclic inhibitors of hepatitis c virus replication
|
AP2009005057A0
(en)
|
2007-05-10 |
2009-12-31 |
Array Biopharma Inc |
Novel peptide inhibitors of hepatitis c virus replication
|
AU2009249443A1
(en)
|
2008-04-15 |
2009-11-26 |
Intermune, Inc. |
Novel macrocyclic inhibitors of hepatitis C virus replication
|
EA201170441A1
(ru)
|
2008-10-15 |
2012-05-30 |
Интермьюн, Инк. |
Терапевтические противовирусные пептиды
|
SG173747A1
(en)
|
2009-02-18 |
2011-09-29 |
Univ Wayne State |
Method for identifying a subpopulation of mammalian cells with distinctive ribosome translation profiles
|
AR075584A1
(es)
|
2009-02-27 |
2011-04-20 |
Intermune Inc |
COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
|
EA201290128A1
(ru)
|
2009-09-28 |
2013-01-30 |
Интермьюн, Инк. |
Новые макроциклические ингибиторы репликации вируса гепатита с
|
CN102712644A
(zh)
|
2009-09-28 |
2012-10-03 |
豪夫迈·罗氏有限公司 |
丙肝病毒复制的新型大环抑制剂
|
WO2011041551A1
(fr)
|
2009-10-01 |
2011-04-07 |
Intermune, Inc. |
Peptides antiviraux thérapeutiques
|